Leukemia and multi-drug resistance: Too many mechanisms of drug resistance or too many doctors resistant?

Leukemia and Lymphoma

Volumn 50, Issue 6, 2009, Pages 1058-1060

  Malagola, Michele ^a   Baccarani, Michele ^b   Russo, Domenico ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FLUDARABINE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; GYRASE INHIBITOR; IDARUBICIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; QUININE; VALSPODAR; VERAPAMIL; VINCRISTINE; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG TREATMENT FAILURE; HUMAN; HYPERBILIRUBINEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHATIC LEUKEMIA; MONOTHERAPY; MULTIDRUG RESISTANCE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

DRUG RESISTANCE, MULTIPLE; HUMANS; LEUKEMIA; P-GLYCOPROTEIN;

EID: 68449086275     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902898255     Document Type: Article

References (23)

1. Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky D, Craddock C, et al. (British Committee for Standards in Haematology). Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006; 135:450-474.
2. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760-3767.
3. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study. Blood 1999;94: 1086-1099.
4. Russo D, Marie JP, Zhou DC, Faussat AM, Delmer A, Maisonneuve L, et al. Coexpression of anionic glutathione-Stransferase (GSTπ) and multidrug resistance (MDR1) genes in acute myeloid and lymphoid leukemias. Leukemia 1994; 8:881-884.
5. Raaijmakers MHGP. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia 2007;21:2094-2102.
6. Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, Michelutti A, et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukaemia with normal karyotype. Haematologica 2006;91:825-828.
7. La Casse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008;27:6252-6275.
8. Kasimir-Bauer S, Beelen D, Flasshove M, Noppeney R, Seeber S, Scheulen ME. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53 and heat shock protein 27 on response to induction therapy and long term survival in patients with de novo acute myeloid leukaemia. Exp Hematol 2002;30: 1302-1308.
9. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 2001;98: 3212-3220.
10. Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, et al. Phase I/ II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol 2001;19:1589-1599.
11. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-1232.
12. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). J Clin Oncol 2004;22:1078-1086.
13. van der Holt B, Lowenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005;106:2646-2654.
14. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, et al. Dose escalation studies of cytarabine, daunorubicine and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukaemia younger than 60 years: Final induction results of cancer and leukaemia group B study 9621. J Clin Oncol 2004;21:4290-4201.
15. Lancet JE, Baer MR, Duran GE, List A, Fielding R, Marcelletti JF, et al. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res, in press.
16. Solary E, Drenou B, Campos L, de Cremoux P, Mugneret F, Moreau P, et al. Quinine as a multidrug resistance inhibitor: A phase 3 multicentric randomized study in adult de novo acute myelogenous leukaemia. Blood 2003;102:1202-1210.
17. Russo D, Piccaluga P, Michieli MG, Michelutti T, Visani G, Gugliotta L, et al. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Ann Hematol 2002; 81:462-466.
18. Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukemia patients. Br J Haematol 2005;131:172-179.
19. Malagola M, Damiani D, Martinelli G, Michelutti A, Cesana B, Vivo AD, et al. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukemia patients. Br J Haematol 2007;136:87-95.
20. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003;102:1466-1473.
21. Mahon FX, Belloc F, Lagarde F, Chollet C, Moreau-Gaudry F, Reiffers J, et al. MDR-1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-2373.
22. Burger H, van Tol H, Boersma AWM, Brok M, Wiemer EAC, Stoter G, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;9:2940-2942.
23. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008;112:2024-2027.